Maxim Group Keeps Their Buy Rating on Amazon (AMZN)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Forte is a 4-star analyst with an average return of 6.8% and a 44.26% success rate. Forte covers the Consumer Cyclical sector, focusing on stocks such as Jakks Pacific, Beyond Inc, and Allbirds.
In addition to Maxim Group, Amazon also received a Buy from Piper Sandler's Thomas Champion in a report issued yesterday. However, on the same day, Wells Fargo reiterated a Hold rating on Amazon (NASDAQ: AMZN).
Based on Amazon's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $155.67 billion and a net profit of $17.13 billion. In comparison, last year the company earned a revenue of $143.31 billion and had a net profit of $10.43 billion
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. Fifteen products delivered at least double-digit sales growth in the second quarter. Outlook Following the strong quarterly performance, Amgen raised fiscal year 2025 adjusted earnings guidance from $20.00-$21.20 per share to $20.20-$21.30 versus the consensus of $20.89. The company raised sales outlook from $34.30 billion-$35.70 billion to $35 billion-$36 billion versus the consensus of $35.29 billion. MariTide in Focus Despite the positive financial results, investor focus remains squarely on the company's experimental weight-loss drug, MariTide. A William Blair analyst noted that investors are 'hyper-focused' on the drug's progress. Part 2 of the Phase 2 chronic weight management study is ongoing in obese patients, with or without type 2 diabetes. Data readout is anticipated in the fourth quarter of 2025. View more earnings on AMGN A Phase 2 study investigating MariTide for type 2 diabetes is ongoing in adults with and without obesity. Data readout is anticipated in the fourth quarter of 2025. Analyst Matt Phipps of William Blair said, 'Given the trial is solely focused on the maintenance setting, we do not believe it will address the key question of tolerability that investors continue to debate.' Analyst Phipps says Amgen shares are up 15% year-to-date, although it remains volatile as investors debate clinical updates with MariTide given the significant market opportunity and competitive landscape. 'We believe Amgen has had meaningful clinical and commercial success with assets including Repatha, Evenity, Blincyto, Tezspire, Imdelltra, and Uplizna that support continued upside on top of the potentially differentiated profile of MariTide, and therefore reiterate our Outperform rating.' Amgen has some near-term headwinds from legacy products, including the recent launch of a biosimilar to Prolia and Xgeva at the end of May 2025 (recent settlement with Sandoz), and the difficulties in gaining more market share with the biosimilar franchises, but the analyst believes clinical catalysts over the next 6 to 12 months will provide meaningful reasons for investor excitement about the long-term growth prospects of the company. Check out . Price Action: AMGN stock is trading lower by 5.10% to $284.97 at last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for AMGN Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for AMGN View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? AMGEN (AMGN): Free Stock Analysis Report This article Amgen Stock Sinks As Market Eyes MariTide's Next Move originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Business Wire
23 minutes ago
- Business Wire
Northern Trust Leaders to Participate in Barclays Global Financial Services Conference on September 9 th
CHICAGO--(BUSINESS WIRE)--Northern Trust Corporation announced today that Chief Financial Officer David Fox and Chief Operating Officer Peter Cherecwich will participate in the Barclays Global Financial Services Conference in New York City on Tuesday, September 9, 2025, at 4:15 p.m. (ET). A live webcast of the event may be accessed via Northern Trust's website ( in the investor relations section. A replay will be available for approximately four weeks after the session date. About Northern Trust Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of June 30, 2025, Northern Trust had assets under custody/administration of US$18.1 trillion, and assets under management of US$1.7 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on Follow us on Instagram @northerntrustcompany or Northern Trust on LinkedIn. Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at
Forbes
24 minutes ago
- Forbes
Feds OK Amazon's Zoox To Operate Robotaxis With No Steering Wheel Or Pedals
A Zoox robotaxi testing in San Francisco Zoox Zoox, the autonomous vehicle company owned by Amazon, has received approval from U.S. regulators to operate its purpose-built electric robotaxis that lack steering wheels, mirrors and conventional vehicle controls on public roads, a necessary step as it prepares to take on Alphabet's Waymo. The National Highway Traffic Safety Administration said it granted Zoox the first-ever exemption from U.S. rules requiring the use of certain features as part of its expanded Automated Vehicle Exemption Program, which applies to all the company's vehicles now on the road. As part of the waiver, Zoox must 'remove or cover' statements claiming its robotaxi meets Federal Motor Vehicle Safety Standards, NHTSA said. The agency also said it's closing an investigation of Zoox's self-certification of its robotaxis. For the latest in cleantech and sustainability news, sign up here for our Current Climate newsletter. The decision is 'a win-win for safety and innovation,' Transportation Secretary Sean Duffy said in a statement. 'America – not China – can and will drive the future of self-driving cars forward.' The waiver clears the way for Zoox, founded 11 years ago, to launch its robotaxi service later this year, first in Las Vegas, with San Francisco, other Bay Area cities, Austin, Miami, Los Angeles and Atlanta to follow. Like Waymo–and unlike Tesla–the Foster City, California-based company has secured permission to operate paid rides in self-driving vehicles in the Golden State. Also like Waymo, Zoox is using far more robust sensors for its autonomous system, including laser lidar, radar, thermal cameras and microphones (to hear emergency vehicles), in addition to digital cameras. With its decision, 'NHTSA has proposed a way to enable Zoox to move forward with confidence,' the company said in an email. 'Through this new exemption process, we are excited to embark on this new path, put these discussions behind us, and move forward, so Zoox can continue to lead the way in autonomous innovation.' A Zoox robotaxi testing in Las Vegas. Zoox Rather than loading up existing vehicles with sensors and computers like Waymo has, Zoox's plan from the outset has revolved around creating a robotaxi service with an electric model built from the ground up. Along with the absence of conventional physical controls, it features sliding doors reminiscent of transit trains and is a bidirectional vehicle, with identical front and rear ends. The toaster-shaped robotaxi has a top speed of 75 miles per hour, though it won't typically exceed 45 mph on urban and suburban runs. It's also intended to operate for up to 16 hours per charge per day and remain in service for at least five years and 100,000 miles. 'We're offering a unique experience for riders that we think they'll prefer,' cofounder and CTO Jesse Levinson told Forbes during a tour of Zoox's robotaxi factory in Hayward, California, in June. 'The ride quality, the carriage-style seating, the roomy interior–we think all of this is going to be what sets us apart.' More From Forbes Forbes Forget Tesla. Amazon's Zoox Is On Track To Be Waymo's Biggest Robotaxi Rival By Alan Ohnsman Forbes Elon Musk's Tesla Robotaxi Rollout Looks Like A Disaster Waiting To Happen By Alan Ohnsman Forbes Inside The Waymo Factory Building A Robotaxi Future By Alan Ohnsman
